MediPharm Labs Completes First Shipment to France

MediPharm Labs Corp., a pharmaceutical company specializing in precision‑based cannabinoids, announced on December 4, 2025 that it has completed its first shipment of medical cannabis products to France. This milestone came under a production agreement with an international medicinal‑cannabis organization — marking MediPharm’s official entry into one of Europe’s rising medical cannabis markets. The company emphasized that this shipment underlines its capacity to meet rigorous European regulatory standards. The French medical‑cannabis market, currently estimated at around US $187.6 million for 2025, is projected to grow to approximately US $213.3 million by 2030 under present regulations. According to CEO David Pidduck, this first production order and export to France “marks our entry into one of Europe’s most promising emerging medical cannabis markets.” He added that it reflects MediPharm’s ability to open new market pathways and deliver “pharmaceutical‑grade products that meet stringent European standards.” As of the third quarter of 2025, international medical cannabis sales contributed 56% of MediPharm’s total revenue, with an 83% year‑over‑year growth in that segment — thanks to expanded products and global distribution. The company now serves customers in about 10 countries worldwide. MediPharm — founded in 2015 — manufactures purified, pharmaceutical‑quality cannabis concentrates, active pharmaceutical ingredients (APIs), and advanced derivative products in a GMP‑certified facility with ISO‑clean rooms. Their 2021 licensing by Canadian regulatory authorities made them the only North American company with a commercial‑scale GMP license for multiple natural cannabinoids. These credentials support their global expansion into complex regulatory jurisdictions like Europe. #MediPharmLabs #MedicalCannabis #FranceMarket #GlobalHealth #SlimScan #GrowthStocks #CANSLIM